Volume | 16,057,388 |
|
|||||
News | - | ||||||
Day High | 49.10 | Low High |
|||||
Day Low | 48.55 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Bristol Myers Squibb Co | BMY | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
49.10 | 48.55 | 49.10 | 48.86 | 48.99 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
105,654 | 16,057,388 | $ 48.79 | $ 783,400,877 | - | 47.58 - 70.935 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:57:39 | 1 | $ 49.15 | USD |
Bristol Myers Squibb (BMY) Options Flow Summary
Bristol Myers Squibb Co Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
98.8B | 2.02B | - | 45.01B | 8.03B | 3.97 | 12.31 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Bristol Myers Squibb News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BMY Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 48.44 | 49.56 | 47.615 | 48.58 | 10,011,431 | 0.71 | 1.47% |
1 Month | 53.05 | 54.475 | 47.615 | 50.49 | 11,001,954 | -3.90 | -7.35% |
3 Months | 49.71 | 55.035 | 47.58 | 50.99 | 15,659,210 | -0.56 | -1.13% |
6 Months | 56.14 | 56.77 | 47.58 | 50.96 | 15,460,443 | -6.99 | -12.45% |
1 Year | 70.34 | 70.935 | 47.58 | 55.37 | 12,682,857 | -21.19 | -30.13% |
3 Years | 66.00 | 81.435 | 47.58 | 63.87 | 11,508,889 | -16.85 | -25.53% |
5 Years | 45.51 | 81.435 | 41.19 | 60.99 | 12,267,205 | 3.64 | 8.00% |
Bristol Myers Squibb Description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power. |